Corporate Funding and Conflicts of Interest: A Primer for Psychologists

American Psychologist

Volumn 62, Issue 9, 2007, Pages 1005-1015

  Pachter, Wendy S ^a   Fox, Ronald E ^b   Zimbardo, Philip ^c   Antonuccio, David O ^d  

^a Human Resources Consultants ^*

^b Stanford University   (United States)

^c UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^d Division of Plastic Surgery   (United States)

Author keywords

APA governance; conflicts of interest; ethics; pharmaceutical industry; Task Force on External Funding

Indexed keywords

EID: 38349175938     PISSN: 0003066X     EISSN: None     Source Type: Journal    
DOI: 10.1037/0003-066X.62.9.1005     Document Type: Article

References (99)

1. Albee G.W. Review of the book Mad in America: Bad science, bad medicine, and the enduring mistreatment of the mentally ill. Journal of Community & Applied Social Psychology 12 (2002) 444-450
2. American Psychological Association. Ethical principles of psychologists and code of conduct. American Psychologist 57 (2002) 1060-1073
3. Angell M. The truth about the drug companies: How they deceive us and what to do about it (2004), Random House, New York
4. Antonuccio D.O., Danton W.G., and McClanahan T.M. Psychology in the prescription era: Building a firewall between marketing and science. American Psychologist 58 (2003) 1028-1043
5. Appleby J. Drugmakers bankroll ethics guidelines on 'freebies': AMA effort intends to remind doctors of rules for accepting handouts. USA Today (2001, April 27) B01
6. Appleby J. Sales pitch: Drug firms use perks to push pills, companies ply doctors to write prescriptions. USA Today (2001, May 16) B01
7. Associated Press. JAMA details doctor-drug company conflicts of interest (2000, October 31). http://www.intelihealth.com/IH/ihtIH/WSIHW000/8124/21291/301912.html Retrieved October 20, 2007, from Aetna InteliHealth: http://www.intelihealth.com/IH/ihtIH/WSIHW000/8124/21291/301912.html
8. Beder S. Global spin: The corporate assault on environmentalism (2002), Chelsea Green, White River Junction, VT
9. Bekelman J.E., Li Y., and Gross C.P. Scope and impact of financial conflicts of interest in biomedical research: A systematic review. JAMA 289 (2003) 454-465
10. Bero L.A. Accepting commercial sponsorship: Disclosure helps-but is not a panacea. British Medical Journal 319 (1999) 653-654
11. Bero, L. A. (2003, July). Risky business: Tobacco industry manipulation of scientific research. Paper presented at the Center for Science in the Public Interest Conference, Conflicted Science: Corporate Influence on Scientific Research and Science-Based Policy, Washington, DC.
12. Bhandari M., Busse J.W., Jackowski D., Montori V.M., Schunemann H., Sprague S., et al. Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. Canadian Medical Journal 170 (2004) 477-480
13. Biotechnology Industry Organization. Biography (2006). http://www.bio.org/aboutbio/biography.asp?sp=00078503 Retrieved December 20, 2006, from http://www.bio.org/aboutbio/biography.asp?sp=00078503
14. Blumenthal D. Academic-industrial relationships in the life sciences. The New England Journal of Medicine 349 (2003) 2452-2459
15. Bodenheimer T. Uneasy alliance-Clinical investigators and the pharmaceutical industry. The New England Journal of Medicine 342 (2000) 1539-1544
16. Bodenheimer T., and Collins R. The ethical dilemma of drugs, money, medicine. The Seattle Times (2001, March 15) B7
17. Bok D. Academic values and the lure of profit. The Chronicle of Higher Education 49 (2003, April 4) B7
18. Brennan T.A., Rothman D.J., Blank L., Blumenthal D., Chimonas S.C., Cohen J.J., et al. Health industry practices that create conflicts of interest: A policy proposal for academic medical centers. JAMA 295 (2006) 429-433
19. Brubaker W. Drug firms lavish pricey gifts on doctors: Ethics debated as freebies flow. The Washington Post (2002, January 19) E01
20. Campbell E.G., Gruen R.L., Mountford J., Miller L.G., Cleary P.D., and Blumenthal D. A national survey of physician-industry relationships. The New England Journal of Medicine 356 (2007) 1742-1750
21. Campbell E.G., Weissman J.S., Clarridge B., Yucel R., Causino N., and Blumenthal D. Characteristics of medical school faculty members serving on institutional review boards: Results of a national survey. Academic Medicine 78 (2003) 831-836
22. Campbell E.G., Weissman J.S., Ehringhaus S., Rao S.R., Moy B., Feibelmann S., et al. Institutional academic-industry relationships. JAMA 298 (2007) 1779-1786
23. Campbell E.G., Weissman J.S., Vogeli C., Clarridge B.R., Abraham M., Marder J.E., et al. Financial relationships between institutional review board members and industry. New England Journal of Medicine 355 (2006) 2321-2329
24. Castleman, B. (2003, July). The asbestos industry's assault on science and society. Paper presented at the Center for Science in the Public Interest conference "Conflicted Science: Corporate Influence on Scientific Research and Science-Based Policy," Washington, DC.
25. Center for Public Integrity. Prescription for power: Drug makers' lobbying army ensures their legislative dominance (2006, May 2). http://www.publicintegrity.org/lobby/report.aspx?aid=685 Retrieved November 10, 2006, from http://www.publicintegrity.org/lobby/report.aspx?aid=685
26. Center for Science in the Public Interest. Lifting the veil of secrecy: Corporate support for health and environmental professional associations, charities, and industry front groups (2003, July 3), Author, Washington, DC
27. Center for Science in the Public Interest. Poll: Science & money don't mix [Press release] (2003, July 3), Author, Washington, DC
28. Choudhry N.K., Stelfox H.T., and Detsky A.S. Relationship between authors of clinical practice guidelines and the pharmaceutical industry. JAMA 287 (2002) 612-617
29. Coyle S.L., for the Ethics and Human Rights Committee, and American College of Physicians-American Society of Internal Medicine. Physician-industry relations. Part 1: Individual physicians [Position paper]. Annals of Internal Medicine 136 (2002) 396-402. http://www.annals.org/cgi/reprint/136/5/396.pdf Retrieved November 15, 2004, from http://www.annals.org/cgi/reprint/136/5/396.pdf
30. Coyle S.L., for the Ethics and Human Rights Committee, and American College of Physicians-American Society of Internal Medicine. Physician-industry relations. Part 2: Organizational issues [Position paper]. Annals of Internal Medicine 136 (2002) 403-406. http://www.annals.org/cgi/reprint/136/5/403.pdf Retrieved November 15, 2004, from http://www.annals.org/cgi/reprint/136/5/403.pdf
31. Dana J., and Loewenstein G. A social science perspective on gifts to physicians from industry. JAMA 290 (2003) 252-255
32. Dember A. Drug firms woo doctors with perks: Billions spent in bid to gain brand loyalty. The Boston Globe (2001, May 20) A1
33. Drinkard J. Drugmakers go furthest to sway Congress. USA Today (2005, April 25) 1B
34. Elliott C. Pharma buys a conscience. The American Prospect 12 (2001, September 24-October 8) 16-20
35. Elliott C. Throwing a bone to the watchdog. Hastings Center Report (2001, March-April) 9-11
36. Ginsberg T. Donations tie drug firms and nonprofits: Many patient groups reveal few, if any, details on relationships with pharmaceutical donors. Philadelphia Inquirer (2006, May 28). http://www.philly.com Retrieved December 2, 2006, from http://www.philly.com
37. Goldfinger S.E., and for the American College of Physicians. Physicians and the pharmaceutical industry [Position paper]. Annals of Internal Medicine 112 (1990, April 15) 624-626
38. Gorner P. Medicine's bible losing its aura of gospel truth. Chicago Tribune (2000, October 29). http://pqasb.pqarchiver.com/chicagotribune/ Retrieved November 15, 2004, from http://pqasb.pqarchiver.com/chicagotribune/
39. Greenberg D.S. Conference deplores corporate influence on academic science. The Lancet 362 (2003) 302-303. http://www.thelancet.com Retrieved September 24, 2003, from http://www.thelancet.com
40. Hall W.J. The ethical dilemma of accepting gifts from drug makers. ACP-ASIM Observer (2001, December). http://www.acponline.org/journals/news/dec01/president.htm Retrieved November 15, 2004, from http://www.acponline.org/journals/news/dec01/president.htm
41. Hampson L.A., Agrawal M., Joffe S., Gross C.P., Verter J., and Emanuel E.J. Patients' views on financial conflicts of interest in cancer research trials. New England Journal of Medicine 355 (2006, November 30) 2330-2337
42. Healy D. Manufacturing consensus. Culture, Medicine, and Psychiatry 30 (2006) 135-156
43. Healy D., and Cattell D. Interface between authorship, industry and science in the domain of therapeutics. British Journal of Psychiatry 183 (2003) 22-27
44. Hensley S. AMA, prescription drug-makers agree ethics policy needs better implementation. The Wall Street Journal (2002, January 21) B4
45. Hensley S. When doctors go to class, industry often foots the bill: Lectures tend to feature pills but drug firms deny influence. The Wall Street Journal (2002, December 4). http://online.wsj.com Retrieved December 22, 2002, from http://online.wsj.com
46. Herxheimer A. Relationships between the pharmaceutical industry and patients' organisations. British Medical Journal 326 (2003) 1208-1210
47. Japsen B. AMA weighs ending sale of doctor data to drug firms. Chicago Tribune (2001, June 18). http://pqasb.pqarchiver.com/chicagotribune/ Retrieved November 15, 2004, from http://pqasb.pqarchiver.com/chicagotribune/
48. Kuehn B.M. Pharmaceutical industry funding for residencies sparks controversy. JAMA 293 (2005) 1572-1580
49. Lenzer J. NIH secrets: Study break. The New Republic (2006, October 24). http://www.tnr.com Retrieved October 30, 2006, from http://www.tnr.com
50. Lexchin J., Bero L.A., Djulbegovic B., and Clark O. Pharmaceutical industry sponsorship and research outcome and quality: Systematic review. British Medical Journal 326 (2003) 1167. http://www.bmj.com/cgi/content/full/326/7400/1167 Retrieved May 31, 2003, from http://www.bmj.com/cgi/content/full/326/7400/1167
51. Lurie P., Almeida C.M., Stine N., Stine A.R., and Wolfe S.M. Financial conflict of interest disclosure and voting patterns at Food and Drug Administration drug advisory committee meetings. JAMA 295 (2006) 1921-1928
52. Maguire P. Ethical issues in CME: Clinical research. ACP-ASIM Observer (2001, May). http://www.acponline.org/journals/news/may01/ethicalprobs.htm Retrieved November 15, 2004, from http://www.acponline.org/journals/news/may01/ethicalprobs.htm
53. Markowitz, G., & Rosner, D. (2003, July). Deceit and denial in the lead industry. Paper presented at the Center for Science in the Public Interest conference "Conflicted Science: Corporate Influence on Scientific Research and Science-Based Policy," Washington, DC.
54. McCarthy M. Medical education companies come under fire in USA. The Lancet 356 (2000) 494
55. McManus R. Lessons from a flood: Zerhouni steers NIH through conflict of interest issue. The NIH Record (2004, September 14). http://nihrecord.od.nih.gov/newsletters/2004/09_14_2004/story01.htm Retrieved December 20, 2006, from http://nihrecord.od.nih.gov/newsletters/2004/09_14_2004/story01.htm
56. Melander H., Ahlqvist-Rastad J., Meijer G., and Beermann B. Evidence b(i)ased medicine-selective reporting from studies sponsored by pharmaceutical industry: Review of studies in new drug applications. British Medical Journal 326 (2003) 1171-1173. http://www.bmj.com/cgi/contents/full/326/7400/1171 Retrieved May 31, 2003, from http://www.bmj.com/cgi/contents/full/326/7400/1171
57. Mello M.M., Clarridge B.R., and Studdert D.M. Academic medical centers' standards for clinical-trial agreements with industry. New England Journal of Medicine 352 (2005) 2202-2210
58. Morin R., and Deane C. Irked drug industry may pull tank funds. The Washington Post (2003, April 8) A31
59. Moses III H., Dorsey E.R., Matheson D.H.M., and Thier S.O. Financial anatomy of biomedical research. JAMA 294 (2005) 1333-1342
60. Mowatt G., Shirran L., Grimshaw J.M., Rennie D., Flanagin A., Yank V., et al. Prevalence of honorary and ghost authorship in Cochrane reviews. JAMA 287 (2002) 2769-2771
61. Moynihan R. Who pays for the pizza? Redefining the relationships between doctors and drug companies: 1. Entanglement. British Medical Journal 326 (2003) 1189-1192
62. Moynihan R. Who pays for the pizza? Redefining the relationships between doctors and drug companies: 2. Disentanglement. British Medical Journal 326 (2003) 1193-1196
63. Mundy A. Dispensing with the truth: The victims, the drug companies, and the dramatic story behind the battle over Fen-Phen (2001), St. Martin's Press, New York
64. Mundy A. Hot flash, cold cash: How a once-respected woman's group went through The Change-with the help of drug industry money. The Washington Monthly (2003, January/February) 35-39
65. Mundy A., and Marcus J. First, do no harm. Boston Magazine (2000, February) 50-55
66. National Association of Attorneys General. Settlement: Fifty attorneys general announce settlement with Pfizer over improper off-label drug marketing [Press release] (2004, May 13), Author, Washington, DC (Available from the National Association of Attorneys General, 2030 M Street NW, 8th Floor, Washington, DC 20036)
67. National Institutes of Health. Evaluation of the impact of the new NIH ethics rules on recruitment and retention (2006, October 26). http://www.nih.gov/about/ethics/evaluationslides.pdf Retrieved December 20, 2006, from http://www.nih.gov/about/ethics/evaluationslides.pdf
68. National Institutes of Health, Office of Legislative Policy and Analysis. Senate Appropriations Committee holds hearing on conflict of interest (2004). http://olpa.od.nih.gov/hearings/108/session2/summaries/conflict.asp Retrieved December 21, 2006, from http://olpa.od.nih.gov/hearings/108/session2/summaries/conflict.asp
69. Needleman H.L. Salem comes to the National Institutes of Health: Notes from inside the crucible of scientific integrity. Pediatrics 90 (1992) 977-981
70. NIH Ethics Concerns: Consulting Arrangements and Outside Awards: Hearings Before the H. Subcomm. on Oversight and Investigations of the Comm. on Energy and Commerce, 108th Cong. 1-827 (2004).
71. Ottaway D.B., and Stephens J. Land trust alliance is rewriting its ethical standards: Organization is responding to increased scrutiny of preservation practices. The Washington Post (2003, October 25) A14
72. Ottaway D.B., and Stephens J. Landing a big one: Preservation, private development. The Washington Post (2003, May 5). http://nl.newsbank.com Retrieved June 12, 2003, from http://nl.newsbank.com
73. Ottaway D.B., and Stephens J. Nonprofit land bank amasses billions: Charity builds assets on corporate partnerships. The Washington Post (2003, May 4). http://nl.newsbank.com Retrieved June 12, 2003, from http://nl.newsbank.com
74. Pear R. Drug makers' battle plan to curb rewards for doctors. New York Times (2002, December 25). http://www.nytimes.com Retrieved December 26, 2002, from http://www.nytimes.com
75. Relman A.S. Separating continuing medical education from pharmaceutical marketing. JAMA 285 (2001, April 18) 2009-2012
76. Relman A.S. Trust me, I'm a scientist (drug companies have too much control over medical research). New Scientist (2001, September 22) 48
77. Relman A.S., and Angell M. America's other drug problem: How the drug industry distorts medicine and politics. The New Republic 227 (2002, December 16) 27-41
78. Rennie, D. (2003, July). Paying the piper, picking the tune: Drug companies and clinical researchers. Paper presented at the Center for Science in the Public Interest conference "Conflicted Science: Corporate Influence on Scientific Research and Science-Based Policy," Washington, DC.
79. Rich E. NIH scientist pleads guilty in accepting $285,000 from Pfizer. The Washington Post (2006, December 9) B2
80. Rowland C. Drug firms lagging on openness: Despite vow, few studies publicized. The Boston Globe (2005, January 9). http://psychrights.org/articles/drug_firms Retrieved December 2, 2006, from http://psychrights.org/articles/drug_firms http://www.washingtonpost.com_lagging_on_openness.htm
81. Seligman K. Psychiatry convention begins in S.F.: Virtual reality tours of schizophrenic mind. San Francisco Chronicle (2003, May 19). http://www.nexis.com Retrieved June 13, 2003, from http://www.nexis.com
82. Shapiro D. Drug companies get too close for med school's comfort. The New York Times (2004, January 20). http://www.nytimes.com Retrieved January 21, 2004, from http://www.nytimes.com
83. Shrader-Frechette, K. (2003, March). Public citizenship and the duties of scientists: Avoiding the best science money can buy. Paper presented at the 54th Annual Meeting of the American Institute of Biological Sciences, Washington, DC.
84. Siegel M. The hungry physician. The Nation (2002, December 30). http://www.thenation.com Retrieved December 22, 2002, from http://www.thenation.com
85. Simon M. Appetite for profit: How the food industry undermines our health and how to fight back (2006), Nation Books, New York
86. Steinbrook R. Conflicts of interest at the NIH-Resolving the problem. New England Journal of Medicine 351 (2004) 955-957
87. Stern C. WorldCom opponents in sync: D.C. firm helps organize protest. The Washington Post (2003, June 20). http://www.washingtonpost.com Available from http://www.washingtonpost.com
88. Supplemental Standards of Ethical Conduct and Financial Disclosure Requirements for Employees of the Department of Health and Human Services, 70 Fed. Reg. 51559 (Aug. 31, 2005) (to be codified at 5 C. F. R. pt. 5501, 5502).
89. Tanner L. Drug companies' ties to schools common. The Joplin Globe (2007, October 16). http://hosted.ap.org/dynamic/stories/U/UNIVERSITIES_DRUG_COMPANIES?SITE= MOJOP&SECTION=HOME&TEMPLATE=DEFAULT Retrieved October 20, 2007, from http://hosted.ap.org/dynamic/stories/U/UNIVERSITIES_DRUG_COMPANIES?SITE= MOJOP&SECTION=HOME&TEMPLATE=DEFAULT
90. Torassa U. Doctors' relationships with drug makers can make for bad medicine. San Francisco Chronicle (2002, February 10) E4
91. Vedantam S. Drug ads hyping anxiety make some uneasy. The Washington Post (2001, July 16). http://www.nexis.com Retrieved June 13, 2003, from http://www.nexis.com
92. Vedantam S. Industry role in medical meeting decried: Symposiums sponsored by pharmaceutical companies trouble some psychiatrists. The Washington Post (2002, May 26). http://nl.newsbank.com Retrieved June 12, 2003, from http://nl.newsbank.com
93. Watkins R.S., and Kimberly J. What residents don't know about physician-pharmaceutical industry interactions. Academic Medicine 79 (2004) 432-437
94. Watkins C., Moore L., Harvey I., Carthy P., Robinson E., and Brawn R. Characteristics of general practitioners who frequently see drug industry representatives: National cross sectional study. British Medical Journal 326 (2003) 1178-1179. http://www.bmj.com/cgi/content/full/326/7400/1178 Retrieved May 31, 2003, from http://www.bmj.com/cgi/content/full/326/7400/1178
95. Wazana A. Physicians and the pharmaceutical industry: Is a gift ever just a gift?. JAMA 283 (2000) 373-380
96. Willman D. Stealth merger: Drug companies and government medical research. Los Angeles Times (2003, December 7) A1
97. Willman D. Scientists add clout in NIH fight: Agency researchers who oppose conflict rules hire lawyers who also serve the drug industry. Los Angeles Times (2005, April 21) A1
98. Willman D. NIH audit criticizes scientist's dealings. Los Angeles Times (2006, September 10) A1
99. Zarin D.A., Tse T., and Ide N.C. Trial registrations at clinical trials.gov between May and October 2005. New England Journal of Medicine 353 (2005, December 29) 2779-2787